Zogenix has filed with the FDA a new drug application for Fintepla, or low-dose fenfluramine, oral solution, indicated to treat seizures associated with Dravet syndrome. The submission was backed by results from two late-stage trials and an open-label extension study that showed a median reduction of 66.8% in the frequency of convulsive seizures per month.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.